Published guidance, NICE advice and quality standards | Guidance

Showing 591 to 600 of 851

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)	TA453	5 July 2017	5 July 2017
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA454	5 July 2017	5 July 2017
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)	TA452	5 July 2017	5 July 2017
Etelcalcetide for treating secondary hyperparathyroidism	TA448	28 June 2017	28 June 2017
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease	TA449	28 June 2017	28 June 2017
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia	TA450	28 June 2017	28 June 2017
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia	TA451	28 June 2017	28 June 2017
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)	TA444	24 May 2017	24 May 2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs	TA445	24 May 2017	24 May 2017
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine	TA440	26 April 2017	26 April 2017